The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases
Y Mao-Draayer, J Sarazin, D Fox, E Schiopu - Clinical immunology, 2017 - Elsevier
Multiple sclerosis (MS) is a prototype autoimmune disease of the central nervous system
(CNS). Currently, there is no drug that provides a cure for MS. To date, all
immunotherapeutic drugs target relapsing remitting MS (RR-MS); it remains a daunting
medical challenge in MS to develop therapy for secondary progressive MS (SP-MS). Since
the approval of the non-selective sphingosine-1-phosphate (S1P) receptor modulator
FTY720 (fingolimod [Gilenya®]) for RR-MS in 2010, there have been many emerging studies …
(CNS). Currently, there is no drug that provides a cure for MS. To date, all
immunotherapeutic drugs target relapsing remitting MS (RR-MS); it remains a daunting
medical challenge in MS to develop therapy for secondary progressive MS (SP-MS). Since
the approval of the non-selective sphingosine-1-phosphate (S1P) receptor modulator
FTY720 (fingolimod [Gilenya®]) for RR-MS in 2010, there have been many emerging studies …